PH26085A - Method for preventing secondary effects of hyperinsulinemia - Google Patents

Method for preventing secondary effects of hyperinsulinemia Download PDF

Info

Publication number
PH26085A
PH26085A PH38126A PH38126A PH26085A PH 26085 A PH26085 A PH 26085A PH 38126 A PH38126 A PH 38126A PH 38126 A PH38126 A PH 38126A PH 26085 A PH26085 A PH 26085A
Authority
PH
Philippines
Prior art keywords
igf
insulin
administered
subjects
day
Prior art date
Application number
PH38126A
Other languages
English (en)
Inventor
Ernst Rudolf Froesch
Hans-Peter Guler
Christoph Schmid
Jurgen Zapf
Original Assignee
Ciba Geigy Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Geigy Ag filed Critical Ciba Geigy Ag
Publication of PH26085A publication Critical patent/PH26085A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PH38126A 1988-02-05 1989-01-31 Method for preventing secondary effects of hyperinsulinemia PH26085A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP88810072 1988-02-05

Publications (1)

Publication Number Publication Date
PH26085A true PH26085A (en) 1992-02-06

Family

ID=8200571

Family Applications (1)

Application Number Title Priority Date Filing Date
PH38126A PH26085A (en) 1988-02-05 1989-01-31 Method for preventing secondary effects of hyperinsulinemia

Country Status (13)

Country Link
US (1) US4988675A (de)
EP (1) EP0331630B1 (de)
JP (1) JP2831017B2 (de)
KR (1) KR0131087B1 (de)
AU (1) AU624595B2 (de)
CA (1) CA1336815C (de)
DE (1) DE68905205T2 (de)
DK (1) DK169233B1 (de)
IE (1) IE63163B1 (de)
IL (1) IL89166A0 (de)
NZ (1) NZ227857A (de)
PH (1) PH26085A (de)
ZA (1) ZA89855B (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6440928B1 (en) 1988-12-06 2002-08-27 Colorado State University Research Foundation Method for treating diabetic neuropathy with NGF
GB8920381D0 (en) * 1989-09-08 1989-10-25 Greater Glasgow Health Board Treatment of insulin-resistant diabetes
US5128320A (en) * 1990-01-18 1992-07-07 Genentech, Inc. Method of restoring normal growth, weight gain or lean body mass in patients with glucocorticoid excess by administering igf-i
US5681814A (en) * 1990-06-07 1997-10-28 Genentech, Inc. Formulated IGF-I Composition
US5126324A (en) * 1990-06-07 1992-06-30 Genentech, Inc. Method of enhancing growth in patients using combination therapy
SE9100099D0 (sv) * 1991-01-11 1991-01-11 Kabi Pharmacia Ab Use of growth factor
SE9201573D0 (sv) * 1992-05-19 1992-05-19 Kabi Pharmacia Ab Use of igf-1
CA2114419A1 (en) * 1992-06-08 1993-12-23 Peter D. Gluckman Use of growth factor igf-i and/or igf-ii
US20070078089A1 (en) * 1992-07-06 2007-04-05 Ishii Douglas N Method for effecting changes in the central nervous system by administration of IGF-I or IGF-II
ES2095086T3 (es) * 1992-10-29 1997-02-01 Genentech Inc Metodo para el tratamiento y la prevencion de la obesidad.
WO1994016722A1 (en) * 1993-01-25 1994-08-04 The Beth Israel Hospital Association Method for modifying, diagnosing, and screening for igf-i sensitive cell barrier properties
US5446024A (en) * 1993-12-17 1995-08-29 Genentech, Inc. Purification of insulin-like growth factor
SE9402331D0 (sv) * 1994-07-01 1994-07-01 Pharmacia Ab New use
SE9402370D0 (sv) * 1994-07-04 1994-07-04 Pharmacia Ab Use of IGF-I
US5728676A (en) * 1994-09-08 1998-03-17 Ciba-Geigy Corporation Use of insulin-like growth factors I and II for inhibition of inflammatory response
US5565428A (en) * 1995-05-22 1996-10-15 Genentech, Inc. Method of administration of IGF-I
US5741776A (en) * 1995-05-22 1998-04-21 Genentech, Inc. Method of administration of IGF-I
EP0766966A3 (de) * 1995-09-08 2001-02-28 Eli Lilly And Company Methode zur Behandlung der Insulinresistenz
US5783556A (en) * 1996-08-13 1998-07-21 Genentech, Inc. Formulated insulin-containing composition
US6025368A (en) * 1997-02-25 2000-02-15 Celtrix Pharmaceuticals, Inc. Method for treating the symptoms of chronic stress-related disorders using IGF
US6015786A (en) * 1997-02-25 2000-01-18 Celtrix Pharmaceuticals, Inc. Method for increasing sex steroid levels using IGF or IGF/IGFBP-3
US6514937B1 (en) 1997-02-25 2003-02-04 Celtrix Pharmaceuticals, Inc. Method of treating psychological and metabolic disorders using IGF or IGF/IGFBP-3
US5916569A (en) * 1997-03-26 1999-06-29 E. Martin Spencer Human erectile dysfunction and methods of treatment
US20030069177A1 (en) * 2000-05-16 2003-04-10 Genentech, Inc. Method for treating cartilage disorders
US6420518B1 (en) 1997-04-04 2002-07-16 Genetech, Inc. Insulin-like growth factor agonist molecules
US6121416A (en) 1997-04-04 2000-09-19 Genentech, Inc. Insulin-like growth factor agonist molecules
CA2356109C (en) * 1999-01-06 2008-04-22 Genentech, Inc. Insulin-like growth factor (igf) i mutant variants
CA2369451C (en) * 1999-04-08 2009-09-22 Genentech, Inc. Composition based on oppositely-charged polypeptides
US6040292A (en) * 1999-06-04 2000-03-21 Celtrix Pharmaceuticals, Inc. Methods for treating diabetes
CA2369839A1 (en) * 1999-06-25 2001-01-04 Minimed, Inc. Compositions of insulin and insulin-related peptide for treating diabetes
AU2001288443B2 (en) * 2000-08-29 2007-06-07 Aurogen Inc. Method for treating the central nervous system by administration of IGF structural analogs
CN100439397C (zh) * 2001-02-09 2008-12-03 基因技术股份有限公司 Igf-1的结晶
AU2002248464A1 (en) 2001-02-21 2002-09-12 Medtronic Minimed, Inc. Stabilized insulin formulations
US7071300B2 (en) * 2001-03-14 2006-07-04 Genentech, Inc. IGF antagonist peptides
US6737401B2 (en) 2001-06-28 2004-05-18 Metronic Minimed, Inc. Methods of evaluating protein formulation stability and surfactant-stabilized insulin formulations derived therefrom
DE10316583A1 (de) * 2003-04-10 2004-10-28 B.R.A.H.M.S Aktiengesellschaft Bestimmung eines midregionalen Proadrenomedullin-Teilpeptids in biologischen Flüssigkeiten zu diagnostischen Zwecken, sowie Immunoassays für die Durchführung einer solchen Bestimmung
WO2005020898A2 (en) * 2003-08-21 2005-03-10 Tercica, Inc. Methods of reducing visceral fat by increasing levels of insulin-like growth factor-i (igf-i)
EP1791551B1 (de) * 2004-08-30 2020-02-26 Ipsen Biopharmaceuticals, Inc. Verfahren und vorrichtung zur diagnose und behandlung von mangelstörung an insulinähnlichem wachstumsfaktor
KR102288366B1 (ko) * 2018-03-09 2021-08-10 경북대학교 산학협력단 한속단 추출물을 유효성분으로 포함하는 비만 예방 또는 치료용 약학적 조성물

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3486216T2 (de) * 1983-04-25 1994-02-17 Chiron Corp Hybrid-DNS-Synthesis von reifen insulinähnlichen Wachstumsfaktoren.

Also Published As

Publication number Publication date
KR890012667A (ko) 1989-09-18
IE890357L (en) 1989-08-05
DK52189D0 (da) 1989-02-03
DE68905205T2 (de) 1993-07-22
NZ227857A (en) 1992-04-28
KR0131087B1 (ko) 1998-04-17
ZA89855B (en) 1989-10-25
JPH01233227A (ja) 1989-09-19
AU2899989A (en) 1989-08-10
DE68905205D1 (de) 1993-04-15
AU624595B2 (en) 1992-06-18
JP2831017B2 (ja) 1998-12-02
EP0331630B1 (de) 1993-03-10
IL89166A0 (en) 1989-09-10
IE63163B1 (en) 1995-03-22
CA1336815C (en) 1995-08-29
US4988675A (en) 1991-01-29
DK169233B1 (da) 1994-09-19
DK52189A (da) 1989-08-06
EP0331630A1 (de) 1989-09-06

Similar Documents

Publication Publication Date Title
EP0331630B1 (de) Verwendung von IGF-I zur Herstellung eines Präparats für die Behandlung und die Verhütung von Nebeneffekten von Hyperinsulinemia bei Diabetikern behandelt mit Insulin
EP0327503B1 (de) Verwendung von IGF I zur Herstellung eines Präparates für die Behandlung von Nierenkrankheiten
US4652548A (en) Pharmaceutical formulations comprising human insulin, human C-peptide, and human proinsulin
Radosevich et al. Effects of morphine on glucose homeostasis in the conscious dog.
EP0732933A1 (de) Methode zur Behandlung von Nierenerkrankungen durch GAbe von FGF - I - und IGFBP - 3
AU780400B2 (en) Methods for treating diabetes
JP2003503356A (ja) 多剤糖尿病治療
AU4098893A (en) Use of IGF-1
US4654324A (en) Human proinsulin pharmaceutical formulations
US4652547A (en) Pharmaceutical formulations comprising human insulin and human proinsulin
US5948757A (en) High dose IGF-1 therapy
Kovacs et al. Hypoglycemic effects of insulin-like growth factor-1 in experimental uremia: can concomitant growth hormone administration prevent this effect?
HU193522B (en) Process for producing pharmaceutical preparations containing human proinsulin
Woodruff et al. Avoidance of surgical hyperglycemia in diabetic patients
NZ241617A (en) Treating and preventing secondary effects of hyperinsulinemia using insulin-like growth factor i (igf i) and lower than normal amounts of insulin
AU681894B2 (en) Use of human growth hormone for preoperative administration
IL104777A (en) Pharmaceutical preparations containing insulin-like growth factor I
RU2157237C2 (ru) Способ коррекции гипергликемии
Stümpel et al. In vivo metabolic activity of des-(B26–B30)-insulin-B25-amide and related analogues in the rat
HK1044895B (en) Methods for treating diabetes
Clemmons Growth Hormone and IGF-I as Anabolic Partitioning Hormones